Clinical Trial Update: A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases [Phase 3]

View source ↗

Summary

Phase III trial evaluating Radium-223 dichloride in symptomatic hormone-refractory prostate cancer with skeletal metastases completed; results were posted in Ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Hormone Refractory Prostate Cancer, Bone Metastases | Phase 3 | Status: COMPLETED | Results posted: 2014-05-07